Obesity treatment has garnered significant attention with the escalating global obese population. Particularly, GLP-1 (Glucagon-like Peptide-1) medications for obesity have emerged as a focal point of global interest. GLP-1, a hormone facilitating insulin secretion from the pancreas, plays a crucial role in reducing blood sugar levels by inhibiting the secretion of glucagon, which elevates blood sugar.
    With GLP-1 gaining popularity as an obesity treatment, especially among celebrities, global pharmaceutical companies are grappling with supply shortages due to overwhelming demand. Consequently, numerous pharmaceutical firms are endeavoring to develop novel obesity treatments, such as micro-needles and oral medications, in addition to the existing injection options.
    Session 2 will delve into the technologies driving the global obesity treatment market, the current investment landscape, and strategies tailored for Korean companies that have developed promising obesity treatment candidates and commenced clinical trials to penetrate the global market.